Tevi Troy

I think it's about 15 years, but that counts once you declare the patent and it doesn't count all the FDA testing. So there's a whole bunch of things that are happening while your patent clock is ticking. And once that clock ticks down, then as you say, the generic is out there on the market and undercutting you on price. And I'm for generics.

I think we should have generics after the patent window expires, but it does make it put a lot of pressure on the pharmaceutical companies to get as much to recoup their investment in the period in which they have the patent still in effect.

I think we should have generics after the patent window expires, but it does make it put a lot of pressure on the pharmaceutical companies to get as much to recoup their investment in the period in which they have the patent still in effect.

I think we should have generics after the patent window expires, but it does make it put a lot of pressure on the pharmaceutical companies to get as much to recoup their investment in the period in which they have the patent still in effect.

Yeah, that's exactly right. We are going to see less innovation, fewer products making it to market, maybe fewer markets, or maybe fewer products being available in America. That's what happened in Europe. Europe, because of their price controls, yes, there are lower prices, but they have fewer products available and they have a much less robust biotechnology sector.

Yeah, that's exactly right. We are going to see less innovation, fewer products making it to market, maybe fewer markets, or maybe fewer products being available in America. That's what happened in Europe. Europe, because of their price controls, yes, there are lower prices, but they have fewer products available and they have a much less robust biotechnology sector.

Yeah, that's exactly right. We are going to see less innovation, fewer products making it to market, maybe fewer markets, or maybe fewer products being available in America. That's what happened in Europe. Europe, because of their price controls, yes, there are lower prices, but they have fewer products available and they have a much less robust biotechnology sector.

So there are advantages to our more free market way of pricing, even though the prices are higher here. I do fear that President Trump's executive order is more just a statement than something that actually will change prices. And you would need congressional action.

So there are advantages to our more free market way of pricing, even though the prices are higher here. I do fear that President Trump's executive order is more just a statement than something that actually will change prices. And you would need congressional action.

So there are advantages to our more free market way of pricing, even though the prices are higher here. I do fear that President Trump's executive order is more just a statement than something that actually will change prices. And you would need congressional action.

But look, Biden did congressional action in terms of the Inflation Reduction Act, horribly named legislation, but also horrible legislation. And they're trying to impose price controls in Medicare. And so, yes, he did it through Congress, but it's still bad policy.

But look, Biden did congressional action in terms of the Inflation Reduction Act, horribly named legislation, but also horrible legislation. And they're trying to impose price controls in Medicare. And so, yes, he did it through Congress, but it's still bad policy.

But look, Biden did congressional action in terms of the Inflation Reduction Act, horribly named legislation, but also horrible legislation. And they're trying to impose price controls in Medicare. And so, yes, he did it through Congress, but it's still bad policy.